Controlling Cardiac Arrhythmias: An Overview With a Historical Perspective

Abstract

During the past decade, several developments in our knowledge of antiarrhythmic drugs have had a major influence on our approach to their use. These developments may be summarized as follows: (1) it has become clear that arrhythmias merit treatment only for the relief of symptoms, with improved quality of life, and for prolongation of survival by reducing arrhythmic deaths; (2) suppression of arrhythmias—symptomatic or asymptomatic—may not necessarily decrease mortality, the net impact on mortality being agent-specific; (3) antiarrhythmic drugs have the propensity to decrease as well as to increase cardiac arrhythmias (producing proarrhythmias); (4) the most important determinant of arrhythmia mortality is the degree and nature of ventricular dysfunction; and (5) only controlled trials have the potential to establish the effect of treatment on mortality in patients with cardiac arrhythmias. To these considerations must be added the advances in nonpharmacologic approaches to controlling cardiac arrhythmias. These include catheter ablation of cardiac arrhythmias, certain surgical techniques that in selected patients offer prospects of cure, and the development of implantable ventricular and atrial cardioverter defibrillators, which allow the evaluation of drugs versus placebo against the background of the defibrillator. This is particularly germane in the case of life-threatening symptomatic ventricular arrhythmias such as sustained ventricular tachycardia and ventricular fibrillation. Antiarrhythmic drugs and implantable devices in the control of arrhythmias cannot be considered in isolation. Their role in mortality reduction needs to be defined alone as well as in combination by controlled clinical trials.